Daniel Bendheim - Phibro Animal President
| PAHC Stock | USD 17.07 0.31 1.85% |
President
Mr. Daniel M. Bendheim is Executive Vice President, Corporationrationrate Strategy and Director of the company. He joined us in 1997. He was appointed Vice President of Business Development in 2001 and was later appointed President, Performance Products in 2004, and then Executive Vice President, Corporationrationrate Strategy in March 2014. He was elected as a director of Phibro in November 2013. Prior to joining us, Mr. Bendheim worked as an analyst at South Coast Capital, a boutique investment bank. Mr. Bendheim obtained a B.A. degree in political science with honors from Yeshiva University in 1993 and a J.D. degree with honors from Harvard Law School in 1996. Mr. Bendheim is a son of Jack C. Bendheim and, together with certain other family members, is a manager of BFI with respect to certain economic rights pertaining to shares of our stock owned by BFI. Mr. Bendheim is qualified to serve on our Board of Directors due to his extensive management experience in all facets of the animal health, mineral nutrition and performance products businesses during his tenure with the Company and his management role within BFI. since 2014.
| Age | 52 |
| Tenure | 10 years |
| Address | Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712 |
| Phone | 201 329 7300 |
| Web | https://www.pahc.com |
Daniel Bendheim Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Bendheim against Phibro Animal stock is an integral part of due diligence when investing in Phibro Animal. Daniel Bendheim insider activity provides valuable insight into whether Phibro Animal is net buyers or sellers over its current business cycle. Note, Phibro Animal insiders must abide by specific rules, including filing SEC forms every time they buy or sell Phibro Animal'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Bendheim over a month ago Disposition of 2500 shares by Daniel Bendheim of Phibro Animal at 11.83 subject to Rule 16b-3 |
Phibro Animal Management Efficiency
The company has return on total asset (ROA) of 0.0372 % which means that it generated a profit of $0.0372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0549 %, meaning that it created $0.0549 on every $100 dollars invested by stockholders. Phibro Animal's management efficiency ratios could be used to measure how well Phibro Animal manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Tangible Assets are forecasted to decline to 0.02. At present, Phibro Animal's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 76.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 15.6 M.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Narendra Lalwani | Esperion Therapeutics | 65 | |
| Richard Bartram | Esperion Therapeutics | 36 | |
Management Performance
| Return On Equity | 0.0549 | ||||
| Return On Asset | 0.0372 |
Phibro Animal Health Leadership Team
Elected by the shareholders, the Phibro Animal's board of directors comprises two types of representatives: Phibro Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phibro. The board's role is to monitor Phibro Animal's management team and ensure that shareholders' interests are well served. Phibro Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phibro Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ramon Fuenmayor, President Region | ||
| Jonathan Bendheim, Director and President MACIE Region and General Manager of Israel Operations | ||
| Damian Finio, Chief Officer | ||
| Daniel Welch, Sr. VP of HR | ||
| Jean Filippi, Pres Region | ||
| Richard Johnson, Interim Officer | ||
| Gerald Carlson, Director | ||
| Mary Malanoski, Independent Director | ||
| Rob Aukerman, President Region | ||
| Jack Bendheim, Chairman of the Board and Presidentident, CEO | ||
| Anthony Andolino, Vice President - Finance, Treasurer | ||
| Michael Giambalvo, President Group | ||
| Sam Gejdenson, Independent Director | ||
| Lisa Escudero, Senior Vice President-Human Resources | ||
| Dean Warras, President - Animal Health & Nutrition, North America | ||
| Larry Miller, Chief Officer | ||
| Thomas Dagger, Senior Vice President General Counsel, Corporate Secretary | ||
| Glenn David, Chief Officer | ||
| Daniel Bendheim, Executive Vice President Director, Corporate Strategy | ||
| David Storbeck, Vice President - Finance, Treasurer | ||
| Judith Weinstein, General VP | ||
| George Gunn, Independent Director | ||
| Thomas Corcoran, Independent Director | ||
| Carol Wrenn, Independent Director | ||
| Samson Li, President Region |
Phibro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phibro Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0549 | ||||
| Return On Asset | 0.0372 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 20.34 M | ||||
| Shares Owned By Insiders | 0.62 % | ||||
| Shares Owned By Institutions | 99.38 % | ||||
| Number Of Shares Shorted | 626.54 K | ||||
| Price To Earning | 11.39 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Phibro Animal in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Phibro Animal's short interest history, or implied volatility extrapolated from Phibro Animal options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Phibro Animal Health using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Phibro Animal Health information on this page should be used as a complementary analysis to other Phibro Animal's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Phibro Stock analysis
When running Phibro Animal's price analysis, check to measure Phibro Animal's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phibro Animal is operating at the current time. Most of Phibro Animal's value examination focuses on studying past and present price action to predict the probability of Phibro Animal's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phibro Animal's price. Additionally, you may evaluate how the addition of Phibro Animal to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Phibro Animal's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phibro Animal. If investors know Phibro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phibro Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Dividend Share 0.48 | Earnings Share 0.37 | Revenue Per Share 24.245 | Quarterly Revenue Growth 0.022 |
The market value of Phibro Animal Health is measured differently than its book value, which is the value of Phibro that is recorded on the company's balance sheet. Investors also form their own opinion of Phibro Animal's value that differs from its market value or its book value, called intrinsic value, which is Phibro Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phibro Animal's market value can be influenced by many factors that don't directly affect Phibro Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phibro Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Phibro Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phibro Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.